BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear Street analysts reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX), buoyed by top-line results on one of the company’s experimental treatments.

Gotistobart is the company’s anti-CTLA4 therapy in second-line or later squamous non-small cell lung cancer (NSCLC), showing tremendous potential. Immediate data shows the therapy reduces death risk by 54% compared to standard chemotherapy. It also boasts a 63% survival rate versus 30% with chemotherapy.

Clear Street remains optimistic that Gotistobart will provide a chemotherapy-free alternative with extended survival benefits for NSCLC patients progressing on PD-L1 inhibitors. Likewise, the research believes the company’s oncology pipeline remains undervalued given its potential to be combined with in-house antibody-drug conjugates.

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases. It is widely recognized for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, sold under the brand name Comirnaty.

While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.